CellCentric raises $220 million to advance oral multiple myeloma drug…

Team S · 2026-05-07T14:34:03.000Z

CellCentric, a Cambridge, UK and Boston-based biotech, has raised a $220 million Series D round led by Venrock to fund mid- and late-stage clinical trials for its lead drug, inobrodib. The funding follows a $120 million Series C co-led by RA Capital Management and Forbion that closed last year. Inobrodib is an oral medicine that blocks two proteins — p300 and CBP — preventing the expression of cancer-driving genes in multiple myeloma. Because it can be taken at home or at the community clinics where most myeloma patients receive treatment, CellCentric argues it offers meaningful flexibility over more complex cellular or infusion-based therapies. The company is currently testing inobrodib in combination with Bristol Myers Squibb's Pomalyst, as well as alongside bispecific antibodies including Pfizer's Elrexfio and Johnson & Johnson's Tecvayli. It is also evaluating the drug in a maintenance setting to prevent cancer from returning. The new capital will support an ongoing Phase 2 study and the planned Phase 3 trial. CellCentric is targeting patients whose disease has progressed despite multiple prior treatments, with a particular focus on those who have already received a bispecific antibody — a patient segment the company believes is underserved by available therapies. Mid-stage data have already suggested the drug can improve response rates when combined with older myeloma medications in heavily pretreated patients. The multiple myeloma treatment landscape has advanced significantly in recent years with the arrival of bispecifics and cell therapies, yet the disease remains largely incurable and most patients eventually relapse. CEO Will West said combining inobrodib with bispecifics could strengthen immune response without additive toxicity, potentially extending both the depth and durability of response beyond what either approach achieves alone.

Member Login Get Access

CellCentric raises $220 million to advance oral multiple myeloma drug… | Newnex